- Home
- RNXT vs MDCX Comparison
RNXT vs MDCX Comparison
Compare RNXT & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- MDCX
- Stock Information
- Founded
- RNXT 2012
- MDCX 2008
- Country
- RNXT United States
- MDCX Canada
- Employees
- RNXT N/A
- MDCX N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- MDCX
- Sector
- RNXT Health Care
- MDCX
- Exchange
- RNXT Nasdaq
- MDCX Nasdaq
- Market Cap
- RNXT 33.8M
- MDCX 29.7M
- IPO Year
- RNXT 2021
- MDCX N/A
- Fundamental
- Price
- RNXT $1.50
- MDCX $2.99
- Analyst Decision
- RNXT Strong Buy
- MDCX Strong Buy
- Analyst Count
- RNXT 2
- MDCX 1
- Target Price
- RNXT $6.50
- MDCX $10.00
- AVG Volume (30 Days)
- RNXT 101.2K
- MDCX 14.9K
- Earning Date
- RNXT 11-13-2024
- MDCX 01-01-0001
- Dividend Yield
- RNXT N/A
- MDCX N/A
- EPS Growth
- RNXT N/A
- MDCX N/A
- EPS
- RNXT N/A
- MDCX N/A
- Revenue
- RNXT N/A
- MDCX N/A
- Revenue This Year
- RNXT N/A
- MDCX N/A
- Revenue Next Year
- RNXT N/A
- MDCX N/A
- P/E Ratio
- RNXT N/A
- MDCX N/A
- Revenue Growth
- RNXT N/A
- MDCX N/A
- 52 Week Low
- RNXT $0.77
- MDCX $1.80
- 52 Week High
- RNXT $1.86
- MDCX $3.23
- Technical
- Relative Strength Index (RSI)
- RNXT 64.78
- MDCX N/A
- Support Level
- RNXT $1.26
- MDCX N/A
- Resistance Level
- RNXT $1.60
- MDCX N/A
- Average True Range (ATR)
- RNXT 0.12
- MDCX 0.00
- MACD
- RNXT 0.01
- MDCX 0.00
- Stochastic Oscillator
- RNXT 72.22
- MDCX 0.00
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.